<DOC>
	<DOC>NCT00285376</DOC>
	<brief_summary>This study is designed to determine the safety and effectiveness of vilazodone for major depressive disorder and to discover genetic markers associated with response. This study will enroll approximately 400 patients.</brief_summary>
	<brief_title>Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response</brief_title>
	<detailed_description>This randomized, double-blind, placebo-controlled, multicenter, 8-week, clinical trial is designed to assess the efficacy and safety of vilazodone and to discover genetic markers of treatment response associated with vilazodone use in adult patients diagnosed with MDD by the DSM-IV-TR criteria. This study will enroll approximately 400 patients.</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Vilazodone Hydrochloride</mesh_term>
	<criteria>Male or female patients 1865 years of age, inclusive. A diagnosis of MDD, single episode or recurrent, according to DSMIVTR (296.2/296.3) with a current Major Depressive Episode of less than two year's duration with a minimum duration of at least 4 weeks. HAMD score ≥ 22. HAMD item 1 (depressed mood) score ≥ 2. Patients must be able to provide written informed consent to participate before beginning any trial related activities. Patients must be able to speak, read and understand English and possess the ability to respond to questions and follow simple instructions. A current (or within 6 months prior to the Screening Visit) Axis I disorder of Post Traumatic Stress Disorder, Eating Disorder, Obsessive Compulsive Disorder (Generalized Anxiety Disorder, Social Phobia or Simple Phobia will be allowed). A history of schizophrenia, schizoaffective disorder or bipolar I or II disorder (with a history of hypomanic or manic episodes). DSMIVTR criteria for substance abuse (alcohol or drugs) within 3 months prior to Screening Visit or substance dependence within 6 months prior to the Screening Visit. Criteria for any of the following DSMIVTR MDD Specifiers: [a] With Catatonic Features; [b] With Postpartum Onset; [c] With Seasonal Pattern.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Depression. Genetics, Pharmacogenetics</keyword>
</DOC>